Literature DB >> 7158626

Nonsecretory multiple myeloma.

R Dreicer, R Alexanian.   

Abstract

The clinical features and disease course of 29 consecutive multiple myeloma patients without monoclonal globulins are described. This variant accounted for 4.7% of all patients with this disease referred over a 17 year time span. Despite bone marrow plasmacytosis and multiple bone lesions in all, hemoglobin levels were less frequently depressed and immunoglobulin values more frequently preserved in comparison with typical myeloma patients. A low tumor mass was defined in 69%, in comparison with 24% of those with evidence of myeloma protein production. Such earlier disease contributed to the long median survival of 39 months in these patients, a duration about 1 year longer than that of typical patients.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7158626     DOI: 10.1002/ajh.2830130406

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  7 in total

1.  Non-secretory multiple myeloma presenting as primary plasma cell leukaemia.

Authors:  A Sureda; J R Pais; J Pascual; M A Pérez Vaquero; J C Hernando
Journal:  Postgrad Med J       Date:  1992-06       Impact factor: 2.401

2.  Comparable outcomes in nonsecretory and secretory multiple myeloma after autologous stem cell transplantation.

Authors:  Shaji Kumar; Waleska S Pérez; Mei-Jie Zhang; Karen Ballen; Asad Bashey; L Bik To; Christopher N Bredeson; Mitchell S Cairo; Gerald J Elfenbein; César O Freytes; Robert Peter Gale; John Gibson; Robert A Kyle; Martha Q Lacy; Hillard M Lazarus; Philip L McCarthy; Gustavo A Milone; Jan S Moreb; Santiago Pavlovsky; Donna E Reece; David H Vesole; Peter H Wiernik; Parameswaran Hari
Journal:  Biol Blood Marrow Transplant       Date:  2008-10       Impact factor: 5.742

3.  Osteoporosis and immunosuppression in multiple myeloma.

Authors:  A M Farrell; R J Powell
Journal:  BMJ       Date:  1989-11-04

4.  Non-secretory lambda multiple myeloma.

Authors:  G Soriono; S Brunet; J Soler; C Guanyabens; C Guarner
Journal:  J Clin Pathol       Date:  1989-05       Impact factor: 3.411

5.  Efficacy and outcome of autologous transplantation in rare myelomas.

Authors:  Curly Morris; Mary Drake; Jane Apperley; Simona Iacobelli; Anja van Biezen; Bo Bjorkstrand; Hartmut Goldschmidt; Jean-Luc Harousseau; Gareth Morgan; Theo de Witte; Dietger Niederwieser; Gosta Gahrton
Journal:  Haematologica       Date:  2010-10-22       Impact factor: 9.941

6.  Non-secretory immunoglobulin E myeloma associated with immunoglobulin G monoclonal gammopathy of undetermined significance.

Authors:  Masako Yasuyama; Toshie Ogasawara; Kuniaki Otsuka; Motohiko Aiba; Kiyotaka Kawauchi
Journal:  Hematol Rep       Date:  2012-07-02

7.  Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients.

Authors:  Michael Ghermezi; Mingjie Li; Suzie Vardanyan; Nika Manik Harutyunyan; Jillian Gottlieb; Ariana Berenson; Tanya M Spektor; Claudia Andreu-Vieyra; Sophia Petraki; Eric Sanchez; Kyle Udd; Cathy S Wang; Regina A Swift; Haiming Chen; James R Berenson
Journal:  Haematologica       Date:  2016-12-29       Impact factor: 9.941

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.